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Millions of Americans are afflicted by obesity and type
2 diabetes mellitus. Obesity is characterized by increased
body adiposity and leads to insulin resistance. Paradoxi-
cally, some conditions that are characterized by a paucity
of fat also cause insulin resistance, namely the syndromes
of lipoatrophy (Fig. 1). The resemblance between the
metabolic abnormalities of these two extreme states of
adiposity emphasizes the importance of fat tissue in en-
ergy homeostasis. This review focuses on the syndromes
of lipodystrophy and lipoatrophy that are at the lean ex-
treme of the spectrum and which are characterized by
near-complete absence of fat.
A Definition of Lipodystrophy, Lipoatrophy,
and Lipoatrophic Diabetes
Lipoatrophy syndromes comprise a heterogeneous clus-
ter of disease states having in common a lack of fat
tissue [1]. The deficiency of adipose tissue can be par-
tial or generalized, and these abnormalities may be con-
genital or acquired [1]. The characteristic loss of fat is
known as “lipoatrophy” whereas an abnormal distribu-
tion of fat is “lipodystrophy”. The term “lipoatrophic
diabetes” refers to patients who have diabetes mellitus
in association with lipoatrophy. It is important to real-
ize that lipodystrophy is a generalized term that encom-
passes lipoatrophy and other abnormalities of adipose tis-
sue such as lipedema or lipomatosis. In this review, we
focus on syndromes characterized primarily by adipocyte
deficiencies throughout the body. Although it is impor-
tant to describe the amount and distibution of adipose
tissue, there is also a distinction between the actual in-
suffiency of adipocytes and preadipocytes that results in
metabolic disturbances and those states of total body fat
deficiency caused by decreased triglyceride storage. In
the latter state, the adipocytes are still basically normal,
but are chronically forced to mobilize their stored triglyc-
erides (e.g. under conditions of chronic caloric depletion,
intense exercise or increased sympathetic drive [2–5]). In
all cases of lipoatrophy there is adipocyte insufficiency
and the metabolic consequences are peripheral insulin re-
sistance and hypertriglyceridemia. It is also interesting to
note that experimental approaches that completely ablate
white adipose tissue lead to the metabolic syndrome re-
gardless of the strategy (see below). These observations
underscore the importance of the adipocyte not only as
storage site for triglycerides; but also as a cell which is ca-
pable of sensing nutrient availability and abundance and
responding with signals that play a regulatory role in en-
ergy storage and partition.
Mechanisms of Disease
Lipodystrophy and lipoatrophy syndromes are character-
ized by decreased adipose tissue. The congenital forms
demonstrate a reduction in adipose tissue throughout life.
The proposed mechanism for these forms of lipodystro-
phy/lipoatrophy results from defects in adipocyte differ-
entiation and function. In the acquired syndromes there is
evidence of normal adipocyte development but then a loss
of adipose tissue later in life which implies a mechanism
of adipocyte destruction. The reduction of adipocytes may
occur via decreased growth and differentiation, increased
apoptosis, or enhanced destruction as may occur in au-
toimmune destruction.
In order to better understand possible etiologies of
lipodystrophy/lipoatrophy syndromes, it is important to
understand normal adipocyte growth and differentiation
(Fig. 2). Normal adipose tissue develops in multiple sites
throughout the body from embryonic mesenchymal cells.
Over the last decade, there have been great advances in
understanding the differentiation program of adipocytes.
Precursor cells are committed to adipogenesis through
transient expression of certain transcription factors such
as the CCAAT/enhancer binding proteins (C/EBPs) and
Peroxisome proliferator activating receptors (PPARs) [6].
Other transcription factors are also involved either in




Fig. 1. Clinical spectrum of adiposity. T1-weighted magnetic resonance images in which lipid appears white. Transverse sections of the torso at the
level of the fifth lumbar vertebra (top panels) and mid-thigh (bottom panels) are shown. (Left) Generalized lipoatrophy, (Center) normal individual
with body mass index of 24 kg/m2 , (Right) an obese individual with body mass index of 38 kg/m2 . Note the marked absence of all fat depots in the
patient with generalized lipoatrophy, with preservation of marrow fat, and a lipid filled liver. Also, the bright color of the muscle is reflective of
lipid-filled myocytes.
Fig. 2. Adipocyte diffrentiation. Mesenchymal precursor cells are committed to the adipogenic pathway in an early step that involves transient
expression of the transcription factors C/EBP β and δ that leads to the formation of preadipocytes. This is followed by expression of PPARγ ,
SREBP1/ADD1 and C/EBPα causing the cells to differentiate into mature adipocytes. How the newly discovered lipodystrophy genes fit into this
scheme is not yet clear (see text for details). Abbreviations: ADD1, adipocyte determination and diffrentiation-dependent factor 1; C/EBP,
CCAAT/enhancer-binding protein; PPAR: peroxisome proliferator-activated receptor; SREBP, sterol regulatory element-binding protein.
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of their ligands (for example sterol regulatory element-
binding protein SREBP1/ adipocyte determination and
diffrentiation-dependent factor 1 ADD1 may regulate syn-
thesis of ligands for PPARγ [7,8]).
Through expression of these nuclear transcription fac-
tors, the cell differentiates into an adipocyte and devel-
ops the ability to store triglycerides, repress cell-cycle
genes and secrete adipocyte-specific hormones. Recently,
a novel molecule called lipin has been cloned as a result of
positional cloning efforts to identify the genetic etiology
of a naturally occurring mouse model with partial lipoa-
trophy and fatty liver. This novel protein has nuclear lo-
calization and is induced during adipocyte differentiation
[9]. Its exact role in the adipocyte differentiation pathway
remains to be identified.
Defects in adipocyte differentiation commitment steps
may lead to adipocyte deficiency; however, the exact con-
trol of normal adipocyte growth and cell cycle are not yet
fully understood. Furthermore, as we will discuss later on
in this review, identification of some of the genes respon-
sible from known human lipoatrophy syndromes did not
easily fit the known pathways in adipocyte differentiation.
Another mechanism by which to lose adipocytes is
through increased destruction of these cells (such as in-
duction of apoptosis). Animal models of lipoatrophy have
been engineered via either distruption of adipogenesis or
induction of adipocyte-death. These models help us un-
derstand the pathophysiology of fat loss. Some of these
models use an adipose-specific promoter/enhancer to in-
troduce a transgene. A review on animal models of lipoa-
trophy can be found elsewhere [10].
When discussing the mechanisms of disease in lipoat-
rophy syndromes, it is important to recognize that the pri-
mary event is adipocyte deficiency and that the metabolic
problems associated with the syndromes are secondary.
The circumstantial evidence for this supposition was based
on the similarity of the metabolic phenotype in a wide
range of human syndromes. However, the direct proof
came with the demonstration that the metabolic pheno-
type was largely reversed upon fat transplantation in a
genetically engineered rodent model of lipoatrophy [11].
Why does fat transplantation reverse metabolic pheno-
type of lipoatrophy? One hypothesis stresses the endocrine
function of the adipocyte. The discovery of the adipocyte
hormone leptin underscored the endocrine function of adi-
pose tissue. Leptin communicates body energy stores to
the neuroendocrine system to control food-intake and en-
ergy expenditure. Leptin has effects (direct or indirect) on
the key organs of metabolism, including the liver, muscle
and pancreas. Another molecular signal originating from
the adipocytes, ACRP 30 [12] (also called adipoQ [13],
APM1 or Adiponectin [14]) was found to be important in
inducing fat oxidation in the muscle and liver [12]. The
list of endocrine signals originating from the adipocyte
is likely to increase (see review by Lustig in this issue).
Lack of adipocytes results in deficiency of these signals,
thus contributing to many of the abnormalities seen in
these syndromes characterized by absence of fat. Thus, it
is possible to view the metabolic aspects of the lipoatro-
phy syndromes as a consequence of the hormonal insuffi-
ciency created by the absence of the organ producing the
hormone.
Classification of Lipoatrophy Syndromes
As mentioned above, absence of fat can be partial or gen-
eralized. and the syndrome can manifest at birth or later
in life [15]. If fat loss is partial, the residual fat undergoes
compensatory hypertrophy. Usually, there is a rough cor-
relation between the severity of metabolic consequences
and the degree of fat loss. There is also an entity called
focal lipoatrophy where the loss of fat involves a single
region in the body. One example of this are the loss of fat
in the gluteal area usually following intramuscular injec-
tions [16]. Therapy with protein hormones, such as insulin
[17,18] and growth hormone [19] may lead to focal lipoa-
trophy. A focal lipoatrophy may also occur on the face re-
ferred to as the Romberg’s syndrome [20]. There are other
specifically described fat distributions reported in the lit-
erature as ‘annular” or “semicircular” lipoatrophy [21,22].
Usually, the isolated loss of fat from a limited body region
is not associated with metabolic consequences, supporting
the hypothesis that a crucial degree of fat loss is required
to observe the metabolic abnormalities.
Genetic Syndromes of Lipoatrophy
and Lipodystrophy
Primary lipoatrophy syndromes
Congenital generalized lipoatrophy (Fig. 3). This con-
dition is also known as Seip-Berardinelli syndrome
[23,24]. In this syndrome, children present with gener-
alized absence of fat within the first year of life. This is
followed by insulin resistance, acanthosis nigricans and
diabetes mellitus before the teen-age years. Hypertriglyc-
eridemia is severe and is accompanied by frequent bouts of
pancreatitis. Affected patients have a high basal metabolic
rate [25] and an increased appetite. Circulating leptin lev-
els are usually quite low [26–28]. This syndrome has an
autosomal recessive mode of inheritance, and has been
described in all ethnic groups. We have observed a sex-
ual dimorphism in the severity of metabolic complica-
tions. Female patients manifest diabetes and hypertriglyc-
eridemia much earlier and usually more severely than the
male siblings in the same family.
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Fig. 3. Congenital generalized lipoatrophy in a 16-year old girl. Picture (Right) and T1-weighted magnetic resonance images (Left). Transverse
sections of the torso at the level of the fifth lumbar vertebra demonstrate markedly deficient subcutaneous and visceral fat (A). Transverse sections of
the midthigh demonstrate absence of subcutaneous, deep, intrafascicular and marrow fat. Note again light-colored, lipid-filled muscle tissue (B). Note
absence of fat throughout the body (C). Notice the differences between these images and those presented in Figures 1 and 2.
Although well described clinically for decades, the
molecular basis for congenital generalized lipoatrophy re-
mained a mystery until quite recently. In the 1970s Foss
et.al. demonstrated the presence of a urinary lipolytic fac-
tor in cases of congenital generalized lipoatropy; however,
these studies have not been reproduced [29].
Initial work to identify the genetic cause of con-
genital generalized lipoatrophy started with candidate
gene approach. The list of excluded genes was long, in-
cluding genes encoding peroxisome-proliferator activated
receptor-gamma, beta-3-adrenergic receptor, leptin, leptin
receptor and lipoprotein lipase among others [30–32].
Progress to identify the disease genes came with posi-
tional cloning studies. The disease was initially mapped
to chromosome 9q34 in some, but not all pedigrees [33].
Thus, it became evident that there were multiple causative
genes. Magre et. al. cloned the first gene responsible
from congenital generalized lipoatrophy using positional
cloning and interval refining [34]. This gene is located on
chromosome 11q13. This new gene was named Seipin as
an attribute to Seip who is one of the first to describe the
syndrome. The protein product of the Seipin gene is most
likely a signaling molecule. It has three trans-membrane
domains and the ligand is not known. The mouse ortho-
logue of the gene is a G-protein related receptor gene [34].
Contrary to the predictions that prevailed prior to the dis-
covery of this gene, Seipin is not abundantly expressed in
the fat cells. It is expressed predominantly in the central
nervous system and especially in the pituitary. Another lo-
cation where it is expressed in high levels is the testes. This
localization outside of adipose tissue implies a greater role
for the central nervous system in energy storage and fuel
metabolism than has currently been known and is likely
to change our views on adipocyte differentiation mecha-
nisms [34].
More recently, the second gene located on chromosome
9q34 was also cloned: 1-acylglycerol-3-phosphate O-
acyltransferase 2 (AGPAT2) gene, AGPAT2 gene. AGPAT-
2 is a 278 amino acid protein, belonging to the fam-
ily of acyltransferases and catalyzes an essential reaction
in the biosynthetic pathway of glycerophospholipids and
triacylglycerol in eukaryotes, namely the conversion of
lysophosphatidic acid to phosphaditic acid [35]. Congen-
ital generalized lipodystrophy is the first documented hu-
man disease due to a genetic defect in this pathway. The ex-
act cause of lipoatrophy is not clear, but we can formulate
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some hypotheses. First, the aberrant AGPAT2 enzyme may
cause lipodystrophy by resulting in “triglyceride-depleted
adipocytes”. However, it is important to note that engi-
neered defects in rodents that interfere with triglyceride
storage alone and result in “empty” adipocyte syndrome,
do not lead to the metabolic consequences so long as
the other functional capabilities (like endocrine function)
of the adipocytes are not altered [36]. It is also likely
that reduced AGPAT2 activity could increase tissue lev-
els of lysophosphatidic acid, which may affect important
adipocyte functions [37,38]. Lysophosphatidic acid is a
ligand for G protein coupled receptors and may have a
role in preadipocyte proliferation and adipogenesis [37–
39]. Decreased AGPAT2 activity could also lead to re-
duced bioavailability of phosphatidic acid and phospho-
glycerols (phosphatidylinositol, phosphatidylcholine and
phosphatidylethanolamine), which are important in intra-
cellular signaling and could affect adipocyte functions
[40]. Future studies are needed to understand the ex-
act mechanism of lipodystrophy seen with mutations in
AGPAT-2. Another interesting question is whether over-
activation of this enzyme can be a causative factor for
human obesity.
There is also interest in identifying phenotypic differ-
ences between the patients harboring mutations on the dif-
ferent genes. First of all, there are some ethnic differences.
So far, patients with Labenese descent have mutations ex-
clusively on the Seipin gene and African American pa-
tients only have mutations on the AGPAT-2 gene. Mental
retardation has been reported in some patients with Seipin
mutations and not with AGPAT-2 mutations. Further work
in this area may elucidate these differences and may shed
some light on the biological function of these two genes.
There are still a few pedigrees with congenital gener-
alized lipoatrophy who do not demonstrate mutations in
either of these identified genes. Research is underway to
identify other gene(s) responsible from congenital gener-
alized lipoatrophy. Rajab et al. reported observations on
17 patients with congenital generalized lipodystrophy in
Oman which suggested the existence of a rare form of
the disorder [41]. All children had widespread absence of
adipose tissue from infancy together with apparent muscle
hypertrophy and hepatomegaly. The patients did not ap-
pear to represent a single homogeneous entity, and could
be subclassified into 2 distinct groups. In the first group
of 7 cases, the features were similar to other published
cases with acanthosis nigricans, raised insulin levels, and
insulin resistance. In this group there was an associa-
tion between the degree of acanthosis nigricans and the
severity of the disorder. Molecular analysis of these cases
showed homozygosity for a mutation at the Berardinelli
Seip Congenital Lipodystrophy 2 (BSCL2) locus on 11q13
in 4 of the 7 cases. In the second group of 10 cases, there
were striking abnormalities in both skeletal and nonskele-
tal muscle, including reduced exercise tolerance, and per-
cussion myoedema. None of these children had insulin
resistance or early endocrine abnormalities. All 10 had hy-
pertrophic pyloric stenosis operated on in the first 6 weeks
of life. The veins were very prominent (phlebomegaly) in
the skin and cutis marmorata was present. Cardiac abnor-
malities with cardiac hypertrophy and arrhythmias were
features later in childhood. There was a history of sudden
death in some of the sibs. There was evidence against ho-
mozygosity in some cases for the known loci of BSCL,
and Rajab et. al. suggested that this group may represent
a new clinical syndrome with lipodystrophy at a different
locus [41].
Familial partial lipodystrophy (FPLD, Dunnigan’s
syndrome) (Fig. 4). Also referred as Kobberling-
Dunnigan syndrome, this condition is inherited in an au-
tosomal dominant fashion. It has been seen mostly in
Caucasians of Northern European descent, but pedigrees
of Asian descent have also been described. It is usually im-
possible to distinguish affected patients from unaffected
ones before the onset of puberty. Patients are born with
normal fat distribution but notice loss of subcutaneous fat
in the extremities and trunk with early puberty. This is
followed by increased fat in the face and neck as puberty
is completed [42,43]. The visceral fat and interfascicular
intramuscular fat depots are preserved [44,45]. While the
disease affects both sexes, the phenotype is much easier to
discern in females leading to ascertainment bias of female
probands. Overall, female patients develop diabetes and
dyslipidemia earlier and more severely. For example, from
our case series, affected females develop diabetes about
73% of the time and hypertriglyceridemia 90% of the time.
In contrast, these incidences are 36% and 45% respec-
tively, in affected male individuals. Our observations are
similar to published observations of another group [46].
An exciting advance in the understanding of the syn-
drome has been the discovery that the disease is caused
by mutations in the lamin A/C gene (LMNA) located at
1q21–23 [47–51]. Lamin A and C are alternatively spliced
products of the same gene and are ubiquitously, but not
equally expressed [52]. They belong to a family of in-
termediate filament proteins that form the nuclear matrix
[53,54], which is located just inside the nuclear membrane.
Lamins dimerize and oligomerize within the structure of
the nuclear matrix [54]. There is developmental regulation
of the expression of lamins in humans.
Besides Dunnigan’s FPLD, multiple other diseases are
associated with mutations in LMNA: Emery Dreyfus mus-
cular dystrophy (a progressive muscular dystrophy of
upper and lower extremity muscles with prominent con-
tractures of ankles and elbows, and cardiac conduction
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abnormalities) [55,56], hereditary limb-girdle muscular
dystrophy [57], a familial cardiomyopathy associated with
conduction abnormalities [58,59], hereditary Charcot-
Marie Tooth Neuropathy type 2 [60] and finally another
complex syndrome with partial lipodystrophy mandibu-
loacral dysplasia [61]. The degree of overlap between
these diseases and FPLD is subject of research. In addition,
how the mutations in the LMNA result in multiple dif-
ferent diseases and how the mutations in a ubiquitously
expressed gene cause various syndromes with a strong
regional distribution are questions still awaiting answers.
As far as FPLD is concerned, investigation of expression
patterns of various lamins in different adipose depots (vis-
ceral versus subcutaneous) did not provide any clues into
the mechanism of disease of FPLD [62]. Likewise, inves-
tigation of the nuclear targeting or interaction with dimer-
ization partner emerin in a common mutant form seen in
FPLD did not elucidate any abnormalities [63].
Partial lipodystrophy associated with dominant negative
mutations on PPAR-gamma gene (late-onset familial
partial lipodystrophy). Barroso and colleagues de-
scribed two probands with severe insulin resistance and
hypertension as well as severe acanthosis nigricans [64].
Initially, no changes in body composition were reported.
However, careful body composition studies revealed that
these patients have significant fat loss in the lower extremi-
ties, particularly in the buttock region. The onset of fat loss
is not at birth, but develops sometime in adulthood. There
is also increased visceral adiposity. Agarwal and Garg de-
scribed another female patient with a different mutation
on PPAR-γ gene who had a similar body fat distribution
without any hypertension and acanthosis nigricans [65].
These observations suggest that dominant-negative mu-
tations of the PPAR-γ gene result in both severe insulin
resistance and also an abnormality in body fat distribution
that manifests later in life.
Congenital syndrome complexes associated
with lipoatrophy
There are also other complex monogeneic syndromes
that are not characterized as primary lipodystrophy syn-
dromes but are associated with abnormal body fat dis-
tribution among other complex abnormalities. Progeria
syndromes such as Werner’s (adult progeria syndrome,
Figure 5(a), [66] and Cockayne’s Syndrome (one of
the juvenile progeria syndromes) [67,68], carbohydrate-
deficient glycoprotein syndrome Type 1 [69], SHORT syn-
drome (an acronym for short stature, hyperextensibility,
hernia, ocular depression, Rieger anomaly and teething
delay) [70,71] and mandibuloacral dysplasia (Fig. 4(b))
[72,73] are among such syndromes. AREDYLD syndrome
(acral, renal and ectodermal dysplasia in association with
generalized lipodystrophy) [74] probably represents an-
other complex progeria syndrome.
Mandibuloacral dysplasia (MAD, Figure 5(b)) is a ge-
netic disorder with multi-system involvement and autoso-
mal recessive inheritance. This extremely rare syndrome is
characterized by multiple skeletal abnormalities, acroost-
eolysis, joint and skin problems and is also associated with
lipodystrophy and metabolic abnormalities [72,73]. In this
condition, the predominant fat loss is from the extremi-
ties and trunk with increased visceral adiposity [75]. Re-
cently Novelli et al. analyzed five consanguineous Italian
families and demonstrated linkage of MAD to chromo-
some 1q21, by use of homozygosity mapping. They then
sequenced the LMNA gene and identified a homozygous
missense mutation (R527H) that was shared by all affected
patients [61]. Patient skin fibroblasts showed nuclei that
presented abnormal lamin A/C distribution and a dysmor-
phic envelope, thus demonstrating the pathogenic effect
of the R527H LMNA mutation [61].
Some unusual congenital associations such as
Vitamin D resistance and persistent Mullerian ducts [76],
retinal pigmentation abnormalities [77] and sensorineural
deafness [78] have been reported in association with lipoa-
trophy in isolated cases. These unusual patients present as
pediatric patients or young adults.
In our case series, we have encountered an autosomal
dominant form of congenital lipodystrophy (characterized
by absence of fat from face, upper trunk, arms and below
the knees) associated with a progressive neurodegenera-
tive disorder (characterized by progressive spinocerebellar
ataxia, pyramidal weakness and spasticity, and autonomic
insufficiency) and congenital cataracts. In this small pedi-
gree, affected individuals also have insulin resistance and
dyslipidemia and both the neurodegenerative disorder and
dyslipidemia are more severe in affected female members
[79].
Acquired Syndromes of Lipoatrophy
Syndromes of acquired generalized lipoatrophy are hard
to categorize due to the apparent heterogeneity of case re-
ports. As it is clear from the genetic syndromes, certain ge-
netic defects do not manifest an abnormality until a certain
point in life. Hence some genetic syndromes can present as
so-called “acquired” syndromes. Especially, in the case of
recessive disorders, the proband may be the only affected
patient and it may be difficult to tease out a genetic pattern
of inheritence. Though there are two eponyms used in the
literature to describe acquired generalized and acquired
partial lipodystrophy syndromes, we will use the descrip-
tive names rather than the eponyms for these syndromes
until better molecular tools enable us to categorize these
syndromes precisely.
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Fig. 4. Dunnigan’s familial partial lipodystrophy. (Top) Pictures of a 26-year old female. Note increased fat around the face/neck (A) and deficiency
in the gluteal region and lower extremities (B). (Bottom) T1-weighted magnetic resonance images. Transverse sections of the torso at the level of the
fifth lumbar vertebra demonstrate markedly deficient subcutaneous and increased visceral fat (C). Transverse sections of the midthigh demonstrate
absence of subcutaneous fat with preservation of deep, intrafascicular and marrow fat (D).
Acquired generalized lipoatrophy
Lawrence described acquired generalized lipoatrophy
with the onset of the disease during childhood [80]. His
original report remains an excellent description of gener-
alized lipoatrophy. Fat loss is usually a remarkable event
leading to a dramatic change in physical features (Fig. 6).
The median time to develop diabetes after loss of fat tis-
sue is about 4 years. Both basal metabolic rate and hepatic
glucose output are increased. While it is known that these
patients lack fully differentiated adipocytes, it is not clear
whether they also lack adipocyte precursors [81]. Patients
with this type of lipodystrophy may have very severe fat
loss, including retroorbital fat and supportive fat in their
hands, feet and genital area. Bone marrow fat is lost in
some cases, while preserved in others.
Acquired partial lipodystrophy
The case reports that refer to Barraquer-Simons syn-
drome describe a wide-range of variation with few shared
features. Patients usually are women in their second or
third decades, who also have a well described autoim-
mune disorder such as scleroderma or glomerulonephritis,
presenting with partial fat loss, [15,82,83]. Fat loss usu-
ally starts from the face and descends downward until the
gluteal line. There is usually increased adiposity in unaf-
fected fat depots (lower extremities). The prevalence of
diabetes and hypertriglyceridemia is about 50% in these
cases and seems to coseggragate with lower total body fat
in our series.
Other associated conditions
Some cases of acquired lipodystrophy occur in the pres-
ence of a population of circulating autoantibodies or an as-
sociation with another autoimmune disease (e.g. juvenile
dermatomyositis) and therefore are thought to be autoim-
mune in nature. There is a clear association of lipodys-
trophy with juvenile dermatomyositis [84–87]. These pa-
tients typically present before teen-age years. The fat loss
can be both generalized or partial. There is usually in-
creased visceral fat despite very severe preipheral fat loss
68 Oral
Fig. 5. (A) Werner’s Syndrome in a 37-year old woman. Clinical features evident include premature aging, allopecia, scleroderma-like changes in the
skin and peripheral lipoatrophy as shown. Insulin-resistant diabetes is an associated feature. (B) Mandibuloacral dysplasia in a 14 year old girl. This
rare recessive syndrome is characterized by acroosteolysis, widened sutures, hypoplastic mandible (shown) and clavicles (shown). Marked peripheral
lipoatrophy and insulin resistance are associated features.
and a specific asymmetric pattern of fat loss on extremities
(Fig. 7).
Panniculitis, a chronic (as defined by lasting 3 months
or longer), generalized inflammation of the subcutaneous
tissue, has been observed either clinically or proven by
biopsy to proceed the loss of fat in some cases of lipodys-
trophy [88]. The evidence for long-sought specific anti-fat
cell autoantibodies or specific activated T-cell clones is
still weak
A portion of acquired lipodystrophy patients are
demonstrated to have low C3 levels [89] and it was spec-
ulated that adipsin, a factor produced by fat cells was re-
sponsible for the loss of fat due to alternative activation
of complement pathway. Generalized or partial fat loss
has been described in association with familial [90] or
acquired hypocomplementemia [91–93].
Some patients infected with HIV while being aggres-
sively treated with protease inhibitors, develop a partial
lipoatrophy. The characteristic loss of subcutaneous fat
occurs in the face, extremities and trunk. In contrast, vis-
ceral fat increases and a “buffalo hump” like that is seen
in Cushing syndrome develops [94–96]. The lipodystro-
phy is accompanied by the development of insulin re-
sistance and hypertriglyceridemia. The changes in body
composition and metabolic parameters are usually appar-
ent within 3 to 6 months of therapy. There is a quicker
onset of this partial lipoatrophy when more than one pro-
tease inhibitor is used. The syndrome is recognized in
both sexes and in pediatric as well as adult patients. Why
do treated HIV patients develop this characteristic pheno-
type? One hypothesis is that an aspartyl protease (like the
HIV protease) may be important in the differentiation of
adipocytes. In support of this hypothesis, several groups
reported that protease inhibitors blocked preadipocyte dif-
ferentiation in vitro [97,98]. Interestingly, some groups
have reported the development of a similar phenotype
when HIV-infected patients are treated aggressively with
other antiretroviral agents other than protease inhibitors
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Fig. 6. Acquired generalized lipoatrophy. The patient had completely normal fat distribution at age 3 8/12 years old (left) and acutely lost her body fat
with a febrile illness at age around age 6 (shown on the right).
(including nucleoside analogues) [99–101]. This suggests
that the lipodystophy may be related to aggressively
treated HIV infection rather than to a specific therapy
[99,102]. Further investigations are underway to better cat-
egorize the fat tissue changes and metabolic consequences
during HIV therapy. While the HIV related lipodsytro-
phy is the most prevalent form of lipodystrophy, the de-




A Recapitulation of Shared Features (Table 2)
Different syndromes of lipodystrophy have a heteroge-
neous clinical presentation; however, findings of insulin-
resistance and hypertriglyceridemia are seen in all forms
of lipoatrophy. A greater loss of adipose tissue is asso-
ciated with an increased severity of the metabolic abnor-
malities. The insulin resistance leads to hyperinsulinemia,
and the associated clinical features of acanthosis nigricans
and hyperandrogenism in female patients.
The reproductive abnormalities are more complicated
than simple hyperandrogenism and polycystic ovaries in
the patients with more severe forms of lipoatrophy. About
50% of all the patients with generalized lipoatrophy and
the majority of the female patients (85%) present with very
low LH levels, more consistent with hypogonadotropic
hypogonadism. This creates a paradox with the findings
on ovarian imaging studies since these usually reveal en-
larged, polycystic ovaries. Hence, it appears that severe
hyperinsulinemia in the most severe cases of lipoatrophy
is sufficient to drive the ovarian enlargement and associ-
ated hyperandrogenism without any apparent stimulation
from the pituitary [103].
Patients with early-onset hyperinsulinemia (as in con-
genital generalized lipoatrophy) develop acromegaloid
features with soft tissue hyperplasia, somatomegaly and
bony abnormalities [104]. Cardiomyopathy is also de-
scribed in some of these cases [105,106].
Another notable finding in the most severely fat defi-
cient patients is their food-seeking behavior. They may
consume large amounts of food (similar to patients with
bulimia) and get the urge to eat frequently. This behavior
is associated with low levels of circulating leptin which
may contribute to the increased appetite [28].
Diabetes will develop in the setting of long-standing
hyperinsulinemia due to beta-cell failure. Diabetic
retinopathy, nephropathy, neuropathy, gastroparesis as
well as coronary heart disease are seen in these patients
with uncontrolled and longstanding hyperglycemia.
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Fig. 7. A case with severe juvenile dermatomyositis and generalized lipodystrophy. The physical appearance of the 19-year old patient is presented
(right). She has severe loss of both muscle and fat tissue. T1-weighted magnetic resonance images of the patient are also presented (left). Transverse
sections of the torso at the level of the fifth lumbar vertebra demonstrate markedly deficient subcutaneous and markedly increased visceral fat (top).
Transverse sections of the midthigh demonstrate asymmetrical absence of subcutaneous fat with preservation of medial subcutaneous fat and marrow
fat (bottom).
There is a high incidence of proteinuria leading to
chronic renal failure among patients with lipoatrophy syn-
dromes. While diabetic nephropathy seem to play a role in
some of these patients, it does not account for all the cases
[107]. The patients with hypocomplementemia develop
membranous glomerulonephritis [108]. Focal segmental
glomerulosclerosis and tubular lipidosis are also among
various kidney pathology that have been described in as-
sociation with lipoatrophy [109].
Patients with lipoatrophy have a dyslipidemia that is
primarily characterized by elevated triglycerides. This is
thought to be secondary to decreased storage site for
triglycerides. There is also strong evidence from animal
models that lipid synthesis is paradoxically increased in
the liver possibly due to decreased signal coming from the
adipocyte that “sufficient” lipid storage is achieved. Lep-
tin may be this crucial signal since this abnormality gets
corrected in one animal model of lipoatrophy upon leptin
replacement [110].
Most patients have a low HDL and some may have
a high LDL. Particularly, the patients with one type of
partial lipodystrophy, namely familial partial lipodys-
rophy of the Dunnigan type have elevated LDL and
a markedly increased risk of coronary artery disease
[111].
It is thought that due to a relative paucity of adipose
tissue, there is excessive accumulation of triglycerides in
multiple locations, most notably in the liver and to some
extent in the muscle [112]. Increased deposition of fatty
acids and triglycerides in the muscle or in the beta-cell
may be responsible for causing insulin resistance (lipo-
toxicity) [113–115]. It is possible that the accumulation
of triglycerides in hepatocytes causes the injury associ-
ated with non-alcoholic steatohepatitis (NASH) [116]. In
patients will all types of lipoatrophy there is an increased
incidence of non-alcoholic steatohepatitis (NASH) com-
pared to both the diabetic and general population. This
condition is seen in at least a third of patients with lipoat-
rophy and may progress into end-stage liver failure.
We have previously observed that the respiratory
quotient (RQ) is elevated in patients with lipoatrophy/
lipodystrophy [117]. The RQ is the ratio of carbon dioxide
production to oxygen consumption and reflects the rela-
tive contributions of carbohydrates and fat in providing
fuel for metabolism. The elevated RQ suggests that there
is an increase in fuel consumption relative to synthesis.
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Table 1. Genetic syndromes of lipoatrophy
Syndrome Lipoatrophy Gene/Locus Inheritence OMIMa
Primary lipoatrophy syndromes
CGLb Generalized 9q34 ARc 269700




Dunnigan syndrome Familial partial 1q21-22 ADe 151660
See text for details Lamin A/C
Late-onset FPLD Familial partial 3p25 AD 604367
See text for details PPAR-γ
Others Numerous distributions Unknown AD/AR N/A
Complex syndromes associated with lipoatrophy
Mandibuloacral dysplasia Congenital, partial 1q21-22 AR 248370
Involves extremities Lamin A/C
Werner syndrome Congenital, partial 8p12 AR 277700
Involves extremities Werner’s Helicase
Cockayne syndrome Congenital, partial 5 AR 216400
Involves extremities CSA
Carbohydrate-deficient Transient, partial 16p.13.3 AR 212065
Glycoprotein syndrome Buttocks PMM1 and 2f
SHORTg syndrome Generalized, congenital Unknown AR 269880
AREDYLDh syndrome Generalized, congenital Unknown Unknown 207780
aOnline-Mendelian Inhertance of Man, reference 132, data base providing information about genetic syndromes.
bCongenital generalized lipoatrophy.
cAutosomal recessive.
dEvidence for genetic heterogeneity.
eAutosomal dominant.
fPhosphomannomutase 1 and 2.
gShort stature, hyperextensibility, hernia, ocular depression, Rieger anomaly, and teething delay.
hAcrorenal field defect, ectodermal dysplasia, and lipoatrophic diabetes, not clear if this is a variation of Berardinelli-Seip syndrome.
Therefore, either the rate of fatty acid oxidation is de-
creased or the rate of lipogenesis is increased. Either
change might contribute to the observed elevation in the
levels of free fatty acids and triglycerides [118]. Further-
more, because fatty acids are known to antagonize in-
sulin’s effects upon glucose metabolism, this provides
another mechanism to account for the state of insulin
resistance [119].
Treatment of Lipoatrophy/Lipodystrophy
The clinical problems requiring treatment in lipoatrophy
syndromes are diabetes, hypertriglyceridemia and cos-
metic problems. The cosmetic problems are quite severe
especially for the female patients and can be emotionally
scarring. It is important not to underestimate the cosmetic
issues while taking care of the metabolic problems. In
patients with lower bady fat abundance and upper body
fat loss, local fat implantation taken from the area of
excess and implanted to the face have produced satis-
fying results. Facial silicon implants in a few patients
with HIV-lipodystrophy have also produced successful
cosmetic recovery. It is important to understand patients’
expectations and wishes and referral to a plastic surgery
center with academic interest in the syndromes may be
valuable.
Treatment of diabetes in lipoatrophy
Although there are several classes of anti-diabetic drugs
marketed in the U.S., it is difficult to achieve good
glycemic control (glycated hemoglobin <7.2%) in most
of the patients with lipoatrophic diabetes. There are
five groups of pharmaceuticals available to treat dia-
betic patients [120] all of which may be used to treat
lipoatrophic patients: insulin secretagogues, biguanides
(metformin), thiazoladienediones (pioglitazone, rosiglita-
zone), intestinal enzyme inhibitors (acarbose), and insulin
itself.
Insulin. Because of their severe insulin resistance, it is
frequently necessary to administer extremely high doses
(e.g., in excess of 1000 units per day) in patients with
various syndromes of lipoatrophy [121]. The volume of
injections are more difficult to tolerate in younger patients.
Nevertheless, insulin remains the only approved medica-
tion for treatment of children with diabetes.
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• Hyperandrogenism in females
• Primary amenorrhea in females
• Muscular hypertrophy
• Cardiomyopathy in some patients
• Hepatomegaly or cirrhosis
• Voracious appetite





• Abnormal cholesterol profile (low HDL,
sometimes high LDL)
• Elevated free fatty acids
• Low leptin levels and other adipocyte hormones such as
adiponectin
• Elevated liver function tests
• Increased glomerular filtration rate
• Proteinuria sometimes in the nephrotic range
• Increased RMR
• Increased respiratory quotient
Radiological characteristics:
• Low body fat by DEXA
• Absent or increased fat compartments on T1 weighted
MRI imaging depending on the syndrome
• Normal bone mineral density by DEXA
• Lytic lesions on long bones and osteosclerosis
• Increased liver and muscle triglyceride content by
NMR spectroscopy
• Hepatic steatosis by ultrasound
Tissue chararecteristics:
• Fat tissue: Absent fat depots
• Muscle: Increased intramyocellular lipids, muscular hypertrophy,
myoedema
• Liver: Non-alcoholic steatohepatitis and/or cirrhosis in the liver
• Kidney: Diabetic nephropathy, membranous glomerulonephritis,
tubular lipidosis, focal segmental glomerulosclerosis
• Islet cells: Hyperplasia, increased lipid droplets, amyloidosis
• Bone marrow: Fat absent in congenital generalized lipoatrophy
Insulin secretagogues. The principal mechanism of ac-
tion for this class of drugs is to promote insulin secretion
by beta cells [122]. Because patients with isolated insulin
resistance may not have an independent defect in insulin
secretion, sulfonylureas are frequently ineffective in pa-
tients with lipoatrophic diabetes.
Metformin. This drug works primarily through inhibit-
ing heptic glucose output. We (and others) have observed
that it may help to decrease insulin requirements in some
patients with lipoatrophy/ lipodystrophy. To our knowl-
edge, there are no systematic trials looking at the efficacy
of this drug in lipoatrophy/lipodystrophy. While the pedi-
atric experience with metformin is growing, it was only
recently approved by the U.S Food and Drug Administra-
tion to be used in children over the age of 10. Therefore,
it needs to be administered by clinicians who have prior
experience with treatment with this drug, ideally in cen-
ters specialized in treating children with unusual forms of
diabetes.
Acarbose. This drug interferes with GI absorption of
many carbohydrates [123]. While we are not aware of sys-
tematic studies of the efficacy of this drug in patients with
lipoatrophy, it has relatively limited efficacy to decrease
glucose levels in type 2 diabetes mellitus.
Thiazolidinediones. This class is the newest addition
to oral hypoglycemic agents. Members of this class are
agonists of peroxisome-proliferator activated receptor-
gamma (PPAR-gamma); thereby, stimulating adipocyte
differentiation [124]. In vivo, this class of drugs functions
as insulin-sensitizers and increase insulin-stimulated glu-
cose uptake by the muscle [125,126]. Troglitazone was
the first member to be approved by the US Food and
Drug Administration. These effects of thiazolidinedione
compounds seemed ideally suited to treat the problems
encountered in lipoatrophy/lipodystrophy syndromes. In
addition, troglitazone exerted favorable effects in an an-
imal model of lipoatrophy [127]. We thus undertook a
treatment trial in these patients with troglitazone [117].
The primary end-points were metabolic control and adi-
pose tissue mass. Six months of troglitazone therapy led
to significant improvement in metabolic control with a re-
duction in HbA1c, triglycerides, and free fatty acids [117].
In addition, there was a small, but statistically significant
increase in body fat [117]. Interestingly, the increase was
predominantly in the subcutaneous compartment. Further-
more, body weight did not change significantly and there
was a decrease in liver size [117]. Despite the favorable ef-
fects of troglitazone, the FDA withdrew troglitazone from
the US market in March 2000 due to concerns over hepa-
totoxicity. The newer members of the class, rosiglitazone
and pioglitazone, remain in clinical use. The preclinical
studies with these two medications suggested that they did
not have the same risk of hepatotoxicity. Since the use of
thiazolidinediones require judicious monitoring for side-
effects, their use should be supervised by clinicians who
are experienced in administering these medications after
careful assessment of risk: benefit ratio.
Treatment of dyslipidemia in lipoatrophy
The dyslipidemia of severe lipoatrophy is difficult to
treat with the currently available therapeutic interventions
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which still results in significant morbidity and mortal-
ity from this condition. Patients with triglyceride levels
over 1000 mg/dl are at risk of developing acute pan-
creatitis. Recurrent episodes lead to pancreatic insuffi-
ciency. Chronically elevated triglycerides in the setting of
hyperinsulinemia and low HDL increase the predisposi-
tion for coronary artery disease. Severely elevated triglyc-
erides may lead to eruptive painful cutaneous xanthomata
[128].
Troglitazone was remarkable in its ability to improve
hypertriglyceridemia in addition to improving glycemia.
As niacin is known to worsen glycemic control, we prefer
to use fibrates and statins in these severely insulin resistant
lipoatrophic patients. Both fibrates and statins may need
to be used in combination with careful monitoring for
side-effects. Again, the pediatric experience with these
medications are extremely limited.
Limitation of caloric intake may be useful for short-
term results, but is not possible to implement for long-
term management as dietary fat is required for proper
growth and development. Medium chain triglycerides and
fish oil have not been tested in a systematic fashion, but
may prove to be useful. We have attempted to use intesti-
nal lipase inhibitors in a few of the most severely affected
pediatric patients with some positive results. Finally, we
have employed long-term plasmapheresis in one patient
with extreme hypertriglyceridemia with moderate clinical
success [128].
Leptin replacement therapy: From the laboratory
to clinical trials
As mentioned earlier, the metabolic abnormalities of di-
abetes and hypertriglyceridemia in lipoatrophy may be
caused by the absence of hormones produced by fat cells.
Shimomura et al. administered one such hormone, leptin,
to lipoatrophic mice. Prior to therapy, these mice exhib-
ited diabetes, hypertriglyceridemia, hepatic steatosis and
severe leptin deficiency. Interestingly, 3 weeks of leptin
therapy ameliorated all the metabolic abnormalities and
also decreased the degree of steatosis in the liver [129].
These results from animal models warranted a clinical trial
which was recently published.
In the published portion of the trial [28], 9 female pa-
tients with various forms of lipodystrophy (5 with congen-
ital generalized, 3 with acquired generalized and 1 with
Dunnigan’s familial partial lipodystrophy) were treated
with 4 months of subcutaneous leptin administered to
achieve physiological concentrations of leptin. Leptin lev-
els increased from a mean of <2 ng/mL to a mean of
12 ng/mL, indicating that that the goal of leptin replace-
ment was largely achieved. There was a remarkable de-
crease in both hyperglycemia and hypertriglyceridemia
as well as improved total body insulin sensitivity and
Table 3. Efficacy of leptin in the treatment of lipodystrophy [28]
(n = 9) [28]
Parameter Baseline 4-Months of therapy P-value
HbA1c (%) 9.1 7.2 <0.001
Triglycerides (mg/dL) 1405 348 <0.001
Free fatty acids 1540 790 <0.05
(mcmole/L)
K-constant @ insulin 0.0071 0.0169 <0.04
tolerance test
Liver volume (cc.s) 3097 1998 <0.002
decreased liver volumes (Table 3). In addition, the repro-
ductive abnormalities were studied in 7 of these patients.
Leptin therapy corrected the amenorrhea seen in 5 of the
5 patients with intact reproductive systems and normal-
ized the attenuated LH response to LHRH stimulation
[103].
This leptin-replacement study is likely to inspire sim-
ilar studies using replacement of adipocyte-specific hor-
mones to treat metabolic abnormalities. Leptin therapy
corrects metabolic abnormalities to a great extent in the
majority of the patients. However, leptin is certainly not
the only hormone made by adipocytes. In fact, in one ani-
mal model of lipoatrophy, combined replacement of both
leptin and adiponectin result in better metabolic control
compared to leptin alone [130]. Haque et al. recently re-
ported that patients with most severe forms of lipodystro-
phy are deficient in adiponectin levels in addition to leptin
[131]. Hence, combined replacement appears as a rational
approach when recombinant adiponectin is available for
human studies.
Conclusions
Human lipodystrophy syndromes encompass a heteroge-
nous spectrum of disorders characterized by loss of
body fat and associated with severe insulin resistance
and hypertriglyceridemia. Studies undertaken to search
the molecular etiologies of these syndromes have un-
covered three completely unexpected genes. Currently
researchers are trying to place these genes on known
paradigms of adipocyte differentiation. All these gene
products are also potential targets for developing novel
therapies against the 21st century epidemic, obesity. On
the other hand, pathophysiological and therapeutic stud-
ies carried out in patients with these disorders and in
animal models have taught important lessons about the
importance of fat tissue in maintaining normal insulin
sensitivity. It is now clear that the adipocyte is an en-




All the data presented in this review were obtained at the
Diabetes Branch of NIDDK, NIH.
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